Jade Biosciences, Inc. (JBIO) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 136.67M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 34.70M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -164.74M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $136.67M | (m) | $34.70M | $-164.74M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $109.15M | (m) | $24.99M | $-133.60M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $93.12M | (m) | $20.01M | $-113.54M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $66.11M | (m) | $11.86M | $-84.97M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $54.43M | (m) | $9.56M | $-74.97M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | (m) | $8.30M | $-53.37M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $53.19M | (m) | $11.31M | $-74.60M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $69.47M | (m) | $13.32M | $-90.26M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $76.03M | (m) | $14.55M | $-94.22M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $70.81M | (m) | $13.72M | $-88.39M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $64.22M | (m) | $11.91M | $-81.41M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $58.63M | (m) | $10.38M | $-75.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $52.53M | (m) | $8.65M | $-67.98M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $44.85M | (m) | $6.84M | $-59.86M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $38.62M | (m) | $5.48M | $-53.24M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $31.45M | (m) | $4.60M | $-45.65M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $24.08M | (m) | $3.95M | $-37.70M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $20.05M | (m) | $3.04M | $-31.26M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $14.99M | (m) | $2.04M | $-23.02M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $7.94M | (m) | $58.00K | $-8.89M | $75.00K | (m) | (m) | -118.52× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |